Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiviral drug resistance.

Literature DB >> 9728000

Antiviral drug resistance.

D Pillay¹, M Zambon.

Abstract

Mesh：

Substances：
Antiviral Agents

Year: 1998 PMID： 9728000 PMCID： PMC1113839 DOI： 10.1136/bmj.317.7159.660

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

18 in total

1. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Authors: S Safrin; C Crumpacker; P Chatis; R Davis; R Hafner; J Rush; H A Kessler; B Landry; J Mills
Journal: N Engl J Med Date: 1991-08-22 Impact factor: 91.245

Review 2. Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV.

Authors: D Pillay
Journal: Commun Dis Public Health Date: 1998-03

3. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.

Authors: A Imrie; A Beveridge; W Genn; J Vizzard; D A Cooper
Journal: J Infect Dis Date: 1997-06 Impact factor: 5.226

4. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors: F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal: N Engl J Med Date: 1997-09-25 Impact factor: 91.245

5. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors: R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal: J Virol Date: 1988-05 Impact factor: 5.103

Review 6. Viral dynamics of HIV: implications for drug development and therapeutic strategies.

Authors: D V Havlir; D D Richman
Journal: Ann Intern Med Date: 1996-06-01 Impact factor: 25.391

7. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient.

Authors: R G Kost; E L Hill; M Tigges; S E Straus
Journal: N Engl J Med Date: 1993-12-09 Impact factor: 91.245

8. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors: N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal: EMBO J Date: 1996-08-01 Impact factor: 11.598

9. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus.

Authors: J Veenstra; R Schuurman; M Cornelissen; A B van't Wout; C A Boucher; H Schuitemaker; J Goudsmit; R A Coutinho
Journal: Clin Infect Dis Date: 1995-09 Impact factor: 9.079

Review 10. Herpes simplex virus resistance to acyclovir: clinical relevance.

Authors: J C Pottage; H A Kessler
Journal: Infect Agents Dis Date: 1995-09

15 in total

Review 1. Viral quasispecies evolution.

Authors: Esteban Domingo; Julie Sheldon; Celia Perales
Journal: Microbiol Mol Biol Rev Date: 2012-06 Impact factor: 11.056

2. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

Authors: Ron Geller; Marco Vignuzzi; Raul Andino; Judith Frydman
Journal: Genes Dev Date: 2007-01-15 Impact factor: 11.361

Review 3. Host-Directed Antiviral Therapy.

Authors: Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal: Clin Microbiol Rev Date: 2020-05-13 Impact factor: 26.132

Antiviral drug resistance.

1. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Review 2. Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV.

3. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.

4. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

5. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Review 6. Viral dynamics of HIV: implications for drug development and therapeutic strategies.

7. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient.

8. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

9. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus.

Review 10. Herpes simplex virus resistance to acyclovir: clinical relevance.

Review 1. Viral quasispecies evolution.

2. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

Review 3. Host-Directed Antiviral Therapy.

4. In vivo antimalarial activity of the endophytic actinobacteria, Streptomyces SUK 10.

Review 5. Nanomedicine to fight infectious disease.

6. Role of cellular lipids in positive-sense RNA virus replication complex assembly and function.

7. Network analysis reveals common host protein/s modulating pathogenesis of neurotropic viruses.

8. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.

Review 9. Photodynamic inactivation of mammalian viruses and bacteriophages.

10. Inhibition of HSP90 attenuates porcine reproductive and respiratory syndrome virus production in vitro.